行業(yè)新聞
當(dāng)前位置：首頁 > 關(guān)于三濟(jì) > 行業(yè)新聞
MediCare將為波立維的相關(guān)基因檢測付費(fèi)
時(shí)間：2013-05-14 10:21:38 來源：三濟(jì)生物 點(diǎn)擊：
NEW YORK (GenomeWeb News) – Transgenomic today announced it has received confirmation of Medicare coverage for its clopidogrel response test.
2012年7月24日，紐約，Transgenomic今天宣布，該公司已經(jīng)收到MediCare將為氯吡格雷藥物檢測付費(fèi)的通知。
National Government Services, the Medicare fiscal intermediary for Connecticut, has confirmed coverage for Transgenomic's Clopidogrel Genetic Absorption Activation Panel, or C-GAAP, providing 48 million Americans currently on Medicare access to the test, formerly called PGxPredict: Clopidogrel.
國家政府（醫(yī)療）服務(wù)局----NGS, 在康涅狄格州為MediCare提供財(cái)務(wù)管理，已經(jīng)確認(rèn)將覆蓋氯吡格雷基因檢測（C-GAAP，氯吡格雷基因-吸收活性委員會），將提供4800萬美國人目前在MediCare接受醫(yī)療服務(wù)，能按需提供檢測，以前稱為“藥物基因組學(xué)預(yù)測：氯吡格雷”
The saliva-based test identifies patients with mutations to their CYP2C19 and ABCB1 genes that cause them to incompletely absorb or activate clopidogrel, which also goes under the brand name Plavix. C-GAAP analyzes markers in both genes to identify those patients who are at genetically heightened risk for major adverse cardiovascular events because of diminished effectiveness of the drug.
通過檢測口腔粘膜組織，能確定病人是否有CYP2C19和ABCB1的基因突變，導(dǎo)致他們對氯吡格雷不能完全吸收或活化。（氯吡格雷的商品名，也即波立維）。C-GAAP檢測這兩個(gè)基因標(biāo)志物，能確定哪些患者由于基因因素，降低了藥物的療效，從而使主要心血管事件的危險(xiǎn)升高。
According to Transgenomic about half of all patients on clopidogrel have markers in CYP2C19 or ABCB1 indicative of compromised absorption or activation of the drug. In 2010, the US Food and Drug Administration issued a "black box" warning to Plavix's label to highlight that patients with the CYP2C19*2/*2 genotype and treated with the drug exhibit higher rates of adverse cardiovascular events than patients with normal CYP2C19 function.
根據(jù)Transgenomic的消息，大約一半使用氯吡格雷的患者帶有CYP2C19或ABCB1的非活性基因，使得吸收或藥物代謝活化不能正常進(jìn)行。2010年，美國FDA發(fā)布了針對波立維的“黑框警示”，警告CYP2C19*2/*2基因型的患者治療時(shí)，比正常CYP2C19功能的患者，心血管事件的危險(xiǎn)程度升高。
Craig Tuttle, CEO of Omaha, Neb.-based Transgenomic, called the Medicare decision a "major commercial milestone" for the firm "and an important step toward widespread use of C-GAAP. Medicare covers about 75 percent of patients for whom the test would be ordered and acceptance by the insurance program "removes a significant barrier for physicians and allows for a more rapid adoption of this important genetic test," he said.
CraigTuttle,Transgenomic公司的CEO認(rèn)為，MediCare的這一決定是“非常關(guān)鍵的決策”，使“氯吡格雷基因-吸收檢測，C-GAAP”得到廣泛應(yīng)用。在美國，MediCare為75%的人群提供醫(yī)療服務(wù)，這些人進(jìn)行氯吡格雷基因檢測，將獲得醫(yī)保報(bào)銷支付。“這將去除醫(yī)生關(guān)切的障礙，大大加速基因檢測的接受度”。
2012年7月24日，紐約，Transgenomic今天宣布，該公司已經(jīng)收到MediCare將為氯吡格雷藥物檢測付費(fèi)的通知。
National Government Services, the Medicare fiscal intermediary for Connecticut, has confirmed coverage for Transgenomic's Clopidogrel Genetic Absorption Activation Panel, or C-GAAP, providing 48 million Americans currently on Medicare access to the test, formerly called PGxPredict: Clopidogrel.
國家政府（醫(yī)療）服務(wù)局----NGS, 在康涅狄格州為MediCare提供財(cái)務(wù)管理，已經(jīng)確認(rèn)將覆蓋氯吡格雷基因檢測（C-GAAP，氯吡格雷基因-吸收活性委員會），將提供4800萬美國人目前在MediCare接受醫(yī)療服務(wù)，能按需提供檢測，以前稱為“藥物基因組學(xué)預(yù)測：氯吡格雷”
The saliva-based test identifies patients with mutations to their CYP2C19 and ABCB1 genes that cause them to incompletely absorb or activate clopidogrel, which also goes under the brand name Plavix. C-GAAP analyzes markers in both genes to identify those patients who are at genetically heightened risk for major adverse cardiovascular events because of diminished effectiveness of the drug.
通過檢測口腔粘膜組織，能確定病人是否有CYP2C19和ABCB1的基因突變，導(dǎo)致他們對氯吡格雷不能完全吸收或活化。（氯吡格雷的商品名，也即波立維）。C-GAAP檢測這兩個(gè)基因標(biāo)志物，能確定哪些患者由于基因因素，降低了藥物的療效，從而使主要心血管事件的危險(xiǎn)升高。
According to Transgenomic about half of all patients on clopidogrel have markers in CYP2C19 or ABCB1 indicative of compromised absorption or activation of the drug. In 2010, the US Food and Drug Administration issued a "black box" warning to Plavix's label to highlight that patients with the CYP2C19*2/*2 genotype and treated with the drug exhibit higher rates of adverse cardiovascular events than patients with normal CYP2C19 function.
根據(jù)Transgenomic的消息，大約一半使用氯吡格雷的患者帶有CYP2C19或ABCB1的非活性基因，使得吸收或藥物代謝活化不能正常進(jìn)行。2010年，美國FDA發(fā)布了針對波立維的“黑框警示”，警告CYP2C19*2/*2基因型的患者治療時(shí)，比正常CYP2C19功能的患者，心血管事件的危險(xiǎn)程度升高。
Craig Tuttle, CEO of Omaha, Neb.-based Transgenomic, called the Medicare decision a "major commercial milestone" for the firm "and an important step toward widespread use of C-GAAP. Medicare covers about 75 percent of patients for whom the test would be ordered and acceptance by the insurance program "removes a significant barrier for physicians and allows for a more rapid adoption of this important genetic test," he said.
CraigTuttle,Transgenomic公司的CEO認(rèn)為，MediCare的這一決定是“非常關(guān)鍵的決策”，使“氯吡格雷基因-吸收檢測，C-GAAP”得到廣泛應(yīng)用。在美國，MediCare為75%的人群提供醫(yī)療服務(wù)，這些人進(jìn)行氯吡格雷基因檢測，將獲得醫(yī)保報(bào)銷支付。“這將去除醫(yī)生關(guān)切的障礙，大大加速基因檢測的接受度”。
